Rapid Serum IgG Reduction as a Potential Indicator of Short-Term Clinical Improvement in AChR-Ab-Positive Generalized Myasthenia Gravis: A Post Hoc Analysis of a Phase III Batoclimab Trial. (PubMed, Neurol Ther) - Oct 14, 2026 - P3 | "Batoclimab rapidly reduced IgG and pathogenic AChR-Ab levels, leading to improved clinical outcomes in patients with gMG. The reduction rate in total IgG may serve as a valuable short-term indicator of clinical response in patients with AChR-Ab-positive gMG following neonatal fragment crystallizable receptor antagonist therapy."
Journal • P3 data • Retrospective data • CNS Disorders • Immunology • Myasthenia Gravis
|
|
Bitao Bu; Chen Zong; Chongbo Zhao; Fei Xiao; Haibing Xiao; Haifeng Li; Haishan Jiang; Hongyu Zhou; Hua Zhang; Huan Yang; Hui Deng; Jianglong Tu; Jianquan Shi; Jianying Xi; Junhong Guo; Qiang Meng; Qing Ke; Qun Xue; Ruisheng Duan; Shuai Zhao; Song Tan; Ting Chang; Wei Li; Wenyu Li; Yali Zhang; Yaoxian Yue; Yuzhou Guan; Zhangyu Zou; Zhijun Li; Zunbo Li
|